| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03058094 Details | 2019-02-04 Interventional | 3 | 0 | Abivertinib Pemetrexed Carcinoma, Non-… NSCLC | Considiering to change the Chemotherapy into Gefitinib - | |||
| NCT02732938 2015-003767-11 Details | 2019-02-04 Interventional | 2 | 22 | Gemcitabine Paclitaxel Adenocarcinoma Metastatic Panc… | Pfizer made a business-related decision on 04May2017 to terminate study based on change in
portfolio prioritization, and is not due to safety or efficacy. The study was terminated prematurely based on the company's change in prioritization for the portfolio and was not due to any safety concerns or regulatory interactions. | |||
| NCT01817699 Details | 2019-02-04 Interventional | 4 | 161 | Cholecalciferol Vitamin D Anemia Renal Insuffici… Renal Insuffici… Vitamin D Defic… Kidney Transpla… | The independent Data Monitoring Committee recommended an early termination. - | |||
| NCT02258607 Details | 2019-02-01 Interventional | 1 | 21 | N-(cyanomethyl)… Trametinib Carcinoma, Non-… Lung Neoplasms Relapsed Metast… | - - | |||
| NCT02244489 Details | 2019-02-01 Interventional | 1 | 16 | Capecitabine N-(cyanomethyl)… Oxaliplatin Adenocarcinoma Relapsed/Refrac… | - - | |||
| NCT02206763 Details | 2019-02-01 Interventional | 1 | 11 | Erlotinib Hydro… N-(cyanomethyl)… Carcinoma, Non-… EGFR Mutated EG… | - - | |||
| NCT02162537 Details | 2019-02-01 Interventional | 3 | 95 | Bevacizumab Pemetrexed Adenocarcinoma … Brain Neoplasms Carcinoma, Non-… Lung Neoplasms Neoplasm Metast… Adenocarcinoma … Cerebral Metast… Non-small Cell … Non-small Cell … | Slow inclusions due in part to a change in practices. The first chemotherapy become a standard
for patients with NSCL with asymptomatic brain metastases. - | |||
| NCT02143804 Details | 2019-02-01 Interventional | 2 | 0 | Molgramostim Sargramostim Urinary Bladder… Bladder Cancer High Grade Non Muscle Inva… | Change in trial design - | |||
| NCT02003573 2013-001752-36 Details | 2019-01-31 Interventional | 1 | 13 | Decitabine Leukemia Leukemia, Myelo… Leukemia, Myelo… | - This study was prematurely discontinued following the decision by the sponsor to discontinue the development of volasertib. | |||
| NCT02828124 Details | 2019-01-30 Interventional | 1/2 | 25 | Nivolumab Carcinoma Carcinoma, Hepa… Hepatocellular … | Business objectives have changed - | |||
| NCT01633060 2012-002571-34 Details | 2019-01-30 Interventional | 3 | 432 | Fulvestrant Breast Neoplasm… Metastatic Brea… | Novartis decided not to pursue further development of buparlisib program (assessment of
moderate PFS benefit with know, but manageable, buparlisib profile). The primary efficacy analysis was completed by 23May16 (primary PFS analysis cutoff date). The study was later terminated and the final safety analysis was conducted up to 08Sep17. One CRF was collecting on 21Sep2017 for survival follow up (LPLV). | |||
| NCT03779100 Details | 2019-01-28 Interventional | 2 | - | Antibodies Immunoglobulins Lenvatinib Cholangiocarcin… Intrahepatic Ch… | Protocol modification - | |||
| NCT03160729 Details | 2019-01-28 Interventional | 4 | 45 | Dexamethasone Kidney Diseases Postoperative C… | Slow recruitment, schanges in standard treatment - | |||
| NCT02606552 Details | 2019-01-28 Interventional | 4 | 9 | Aspirin Clopidogrel Atrial Fibrilla… Coronary Artery… Coronary Diseas… Myocardial Isch… | The number of patients registered for the study was low and it was expected to be difficult to
derive the study results. - | |||
| NCT02373462 Details | 2019-01-28 Interventional | 4 | 1 | Antihypertensiv… Olmesartan Intermittent Cl… Peripheral Arte… Peripheral Arte… | The data of the paper referenced in the preparation of the protocols in this task were
manipulated and the paper was withdrawn. - | |||
| NCT01372202 Details | 2019-01-25 Interventional | 2 | 31 | Fluorouracil Oxaliplatin Paclitaxel Esophageal Neop… Esophageal Canc… | Study stopped due to early stopping rule - | |||
| NCT02412475 Details | 2019-01-24 Interventional | 1 | 3 | Cytarabine Decitabine Fludarabine Sorafenib Vorinostat Leukemia, Myelo… Leukemia, Acute… | We opened a competing study with the TACL consortium - | |||
| NCT03079505 Details | 2019-01-23 Interventional | 3 | 10 | Dasatinib Nilotinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Chronic Myeloid… | Protocol Deviation - | |||
| NCT02646800 Details | 2019-01-23 Interventional | 4 | 105 | Micafungin Aspergillosis Candidiasis Mycoses | Due to administrative reasons - | |||
| NCT01185509 Details | 2019-01-23 Interventional | 2 | 31 | Trastuzumab Vinorelbine Breast Neoplasm… Breast Cancer Metastatic Brea… | Not enough confirmed responses to continue treatment. The study terminated early due to insufficient response per statistical design. |